{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:44:24Z","timestamp":1792626264938,"version":"4.5.0"},"reference-count":24,"publisher":"SAGE Publications","issue":"13","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lupus"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>In recent years, there have been a number of studies suggesting that POTS may have an autoimmune etiology. This study examined whether the prevalence of antinuclear antibodies (ANA), other markers of autoimmunity and co-morbid autoimmune disorders is higher in patients with POTS than in the general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Medical records of 100 consecutive patients with POTS evaluated at our clinic were reviewed. In this cohort (90% females, mean age 32, range 13\u201354 years), 25% had positive ANA, 7% had at least one positive aPL antibody and 31% had markers of autoimmunity. When compared to the general population, patients with POTS had a higher prevalence of ANA (25% vs. 16%, OR 1.8, CI 1.1\u20132.8, p\u2009&lt;\u20090.05), aPL antibody (7% vs. 1%, OR 7.5, CI 3.4\u201316.1, p\u2009&lt;\u20090.001) and co-morbid autoimmune disorders (20% vs. highest estimated 9.4%, OR 2.4, CI 1.5\u20133.9, p\u2009&lt;\u20090.001). The most prevalent autoimmune disorder was Hashimoto\u2019s thyroiditis (11% vs. up to 2%, OR 6.1, CI 3.2\u201311.3, p\u2009&lt;\u20090.001), followed by RA (4% vs. up to 1%, OR 4.1, CI 1.5\u201311.2, p\u2009&lt;\u20090.01) and SLE (2% vs. up to 0.12%, OR 17, CI 4.1\u201369.7, p\u2009&lt;\u20090.001). The prevalence of CVID was very high (2% vs. 0.004%, OR 510.2, CI 92.4\u20132817.8, p\u2009&lt;\u20090.001), while celiac disease showed a nonsignificant trend toward increased prevalence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with POTS have a higher prevalence of autoimmune markers and co-morbid autoimmune disorders than the general population. One in four patients have positive ANA, almost one in three have some type of autoimmune marker, one in five have a co-morbid autoimmune disorder, and one in nine have Hashimoto\u2019s thyroiditis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0961203315587566","type":"journal-article","created":{"date-parts":[[2015,6,2]],"date-time":"2015-06-02T20:00:57Z","timestamp":1433275257000},"page":"1364-1369","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":107,"title":["Autoimmune markers and autoimmune disorders in patients with postural tachycardia syndrome (POTS)"],"prefix":"10.1177","volume":"24","author":[{"given":"S","family":"Blitshteyn","sequence":"first","affiliation":[{"name":"Department of Neurology, State University of New York at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,6,1]]},"reference":[{"key":"bibr1-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)61027-6"},{"key":"bibr2-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2013.03.002"},{"key":"bibr3-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000755"},{"key":"bibr4-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-014-0251-0"},{"key":"bibr5-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.144501"},{"key":"bibr6-0961203315587566","first-page":"401739","volume":"2014","author":"Avery TY","year":"2014","journal-title":"J Immun Res"},{"key":"bibr7-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1007\/1-84628-009-5_2"},{"key":"bibr8-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.09.008"},{"key":"bibr9-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012595961-2\/50038-X"},{"key":"bibr10-0961203315587566","volume-title":"Epidemiology of the rheumatic diseases","author":"Silman AJ","year":"2001","edition":"2"},{"key":"bibr11-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199901)42:1<46::AID-ANR6>3.0.CO;2-2"},{"key":"bibr12-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.219"},{"key":"bibr13-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60326-1"},{"key":"bibr14-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1002\/art.23177"},{"key":"bibr15-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.10.013"},{"key":"bibr16-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.01.018"},{"key":"bibr17-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2012.11.009"},{"key":"bibr18-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7465-x"},{"key":"bibr19-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314524468"},{"key":"bibr20-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12272"},{"key":"bibr21-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.278448"},{"key":"bibr22-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1097\/NRL.0b013e3181ebe59f"},{"key":"bibr23-0961203315587566","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2010.10.002"},{"key":"bibr24-0961203315587566","unstructured":"Assessment of antibodies and inflammatory markers in postural tachycardia syndrome. ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/show\/NCT02196376 (accessed 4 February 2015)."}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0961203315587566","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0961203315587566","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0961203315587566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:15:55Z","timestamp":1777677355000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0961203315587566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,1]]},"references-count":24,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1177\/0961203315587566"],"URL":"https:\/\/doi.org\/10.1177\/0961203315587566","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,1]]}}}